Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Oral Vernakalant for AF/AFL Recurrence
NCT00267930Phase 2Completed
- Sponsor
- ADVANZ PHARMA
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of vernakalant in Atrial fibrillation (AFib), atrial flutter (AFL), sponsored by ADVANZ PHARMA. Started Dec 2005; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT00267930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267930.